GS-4774

BIOLOGICAL4 trials

Sponsors

Gilead Sciences

Conditions

Chronic HBV InfectionChronic Hepatitis BHealthy Volunteers

Phase 1

A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults

CompletedNCT01779505

Gilead SciencesHealthy Volunteers

Start: 2013-01-31End: 2013-08-31Updated: 2014-01-08

Phase 2

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

CompletedNCT01943799

Gilead SciencesChronic HBV Infection

Start: 2013-09-13End: 2015-03-03Updated: 2019-11-01

Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment

CompletedNCT02174276

Gilead SciencesChronic Hepatitis B

Start: 2014-07-24End: 2018-05-30Updated: 2019-06-04

Unknown Phase

Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection

TerminatedNCT02258581

Gilead SciencesChronic Hepatitis B

Start: 2014-12-09End: 2017-08-14Updated: 2017-10-03

Related Papers

Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis.

2019-03-28104 citations

Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.

2016-05-19135 citations

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: A randomized study

Vaccine2014-07-18100 citations